While a number of new systemic antifungals have been licensed in recent years (most recently isavuconazole), there is still an urgent need for new drugs, particularly from novel chemical classes – as reviewed by Perfect (2017) in Nature Reviews Drug Discovery. Shortcomings of current drugs include:
- Toxicity and unpleasant side effects
- Suboptimal pharmacokinetic properties, such as short half-life or poor penetration into certain tissues or sanctuary sites
- Antifungal resistance (intrinsic or acquired)
It should be noted that many FDA-approved antifungals (especially newer formulations) are unavailable to patients in many healthcare systems due to cost and in some cases lack of local registration.
![](http://en.fungaleducation.org/wp-content/uploads/2020/07/spacer-tricolor2-1.png)
New antifungals in human trials
For a full list of clinical trials please visit Clinicaltrials.gov (NIH worldwide) or NIHR Be Part of Research (NHS, UK).
Recent progress on new antifungals currently in Phase 2 or 3 trials was reviewed in Science by Kupferschmidt (2019).
![](http://en.fungaleducation.org/wp-content/uploads/2019/12/new-antifungals-4-1-1024x726.jpg)
@AmplyxPharma are sponsoring a Phase 2 trial (NCT03604705) testing fosmanogepix (APX001, a fast-tracked first-in-class Gwt1 inhibitor) against candidaemia.
F2G are sponsoring a Phase 2b trial (FORMULA-OLS, NCT03583164) testing olorofim (F901318, an orotomide) against invasive fungal infections (Aspergillus, Fusarium, Lomentospora, Scedosporium, invasive infections) in ~100 patients lacking other treatment options.
@CidaraThera are sponsoring a Phase 3 RCT (ReSTORE, NCT03667690) testing IV rezafungin (CD101, an echinocandin) against candidaemia and invasive candida in ~218 patients (placebo = IV caspofungin).
Several trials by @Scynexis are underway for ibrexafungerp (SCY-078, first-in-class triterpene), including as combination therapy with voriconazole for treating invasive pulmonary aspergillosis (Phase 2, SCYNERGIA, NCT03672292). It is also in Phase 3 trials for recurrent vulvovaginal thrush (CANDLE, NCT04029116) and acute vulvovaginal thrush (Vanish306, NCT03987620).
![](http://en.fungaleducation.org/wp-content/uploads/2020/07/spacer-tricolor2-1.png)
New antifungals in discovery or preclinical phases
For more information and recent publications please see the New Antifungals section of the Aspergillus & Aspergillosis website.
![](http://en.fungaleducation.org/wp-content/uploads/2020/07/spacer-tricolor2-1.png)
Other interventions
Many clinical trials are underway for purposes other than registering new antifungals, for example:
- Diagnostics and biomarker-directed treatment selection
- Devices (e.g. antifungal central line locks)
- Delivery systems (e.g. inhaled amphotericin, clotrimazole socks)
- Regimens and combined therapies
- Antifungal stewardship